These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 39101355)

  • 1. Organic solvent-free benznidazole nanosuspension as an approach to a novel pediatric formulation for Chagas disease.
    Magi MS; Lopez-Vidal L; García MC; Stempin CC; Marin C; Maletto B; Palma SD; Real JP; Jimenez-Kairuz AF
    Ther Deliv; 2024; 15(9):699-716. PubMed ID: 39101355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
    Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
    Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies.
    Scalise ML; Arrúa EC; Rial MS; Esteva MI; Salomon CJ; Fichera LE
    Am J Trop Med Hyg; 2016 Aug; 95(2):388-93. PubMed ID: 27246447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benznidazole microcrystal preparation by solvent change precipitation and in vivo evaluation in the treatment of Chagas disease.
    Maximiano FP; de Paula LM; Figueiredo VP; de Andrade IM; Talvani A; Sá-Barreto LC; Bahia MT; Cunha-Filho MS
    Eur J Pharm Biopharm; 2011 Aug; 78(3):377-84. PubMed ID: 21397015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel solid dispersions of benznidazole: preparation, dissolution profile and biological evaluation as alternative antichagasic drug delivery system.
    Fonseca-Berzal C; Palmeiro-Roldán R; Escario JA; Torrado S; Arán VJ; Torrado-Santiago S; Gómez-Barrio A
    Exp Parasitol; 2015 Feb; 149():84-91. PubMed ID: 25583295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benznidazole in vitro dissolution release from a pH-sensitive drug delivery system using Zif-8 as a carrier.
    de Moura Ferraz LR; Tabosa AÉGA; da Silva Nascimento DDS; Ferreira AS; Silva JYR; Junior SA; Rolim LA; Rolim-Neto PJ
    J Mater Sci Mater Med; 2021 May; 32(6):59. PubMed ID: 33999312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tailoring microstructural, drug release properties, and antichagasic efficacy of biocompatible oil-in-water benznidazol-loaded nanoemulsions.
    Streck L; Sarmento VHV; de Menezes RPRPB; Fernandes-Pedrosa MF; Martins AMC; da Silva-Júnior AA
    Int J Pharm; 2019 Jan; 555():36-48. PubMed ID: 30448310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced delivery of fixed-dose combination of synergistic antichagasic agents posaconazole-benznidazole based on amorphous solid dispersions.
    Figueirêdo CBM; Nadvorny D; Vieira ACQM; Schver GCRM; Soares Sobrinho JL; Rolim Neto PJ; Lee PI; Soares MFR
    Eur J Pharm Sci; 2018 Jul; 119():208-218. PubMed ID: 29679707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.
    Li X; Yi S; Scariot DB; Martinez SJ; Falk BA; Olson CL; Romano PS; Scott EA; Engman DM
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33986194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of novel benznidazole formulations: physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease.
    Palmeiro-Roldán R; Fonseca-Berzal C; Gómez-Barrio A; Arán VJ; Escario JA; Torrado-Durán S; Torrado-Santiago S
    Int J Pharm; 2014 Sep; 472(1-2):110-7. PubMed ID: 24928135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole.
    Fernández ML; Marson ME; Ramirez JC; Mastrantonio G; Schijman AG; Altcheh J; Riarte AR; Bournissen FG
    Mem Inst Oswaldo Cruz; 2016 Mar; 111(3):218-21. PubMed ID: 26982179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough.
    Morilla MJ; Montanari JA; Prieto MJ; Lopez MO; Petray PB; Romero EL
    Int J Pharm; 2004 Jul; 278(2):311-8. PubMed ID: 15196636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D printed benznidazole tablets based on an interpolyelectrolyte complex by melting solidification printing process (MESO-PP): An innovative strategy for personalized treatment of Chagas disease.
    Magi MS; Lopez-Vidal L; Rega P; Ibarra M; Palma SD; Jimenez Kairuz A; Real JP
    Int J Pharm; 2024 Sep; 662():124476. PubMed ID: 39029635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations.
    Leite DI; Fontes FV; Bastos MM; Hoelz LVB; Bianco MDCAD; de Oliveira AP; da Silva PB; da Silva CF; Batista DDGJ; da Gama ANS; Peres RB; Villar JDF; Soeiro MNC; Boechat N
    Chem Biol Drug Des; 2018 Sep; 92(3):1670-1682. PubMed ID: 29745048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease?
    Seremeta KP; Arrúa EC; Okulik NB; Salomon CJ
    Colloids Surf B Biointerfaces; 2019 May; 177():169-177. PubMed ID: 30731393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and Characterization of Poloxamer 407 Solid Dispersions as an Alternative Strategy to Improve Benznidazole Bioperformance.
    Simonazzi A; Davies C; Cid AG; Gonzo E; Parada L; Bermúdez JM
    J Pharm Sci; 2018 Nov; 107(11):2829-2836. PubMed ID: 30005984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New 2-nitroimidazole-N-acylhydrazones, analogs of benznidazole, as anti-Trypanosoma cruzi agents.
    Pitombeira MCSR; Júnior PAS; Murta SMF; Romanha A; Luccas PH; Nonato MC; Rocha REO; Ferreira RS; da Silveira FF; Castelo-Branco FS; Carvalho AS; Boechat N
    Arch Pharm (Weinheim); 2024 Jul; 357(7):e2400059. PubMed ID: 38627301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection.
    Rial MS; Scalise ML; López Alarcón M; Esteva MI; Búa J; Benatar AF; Prado NG; Riarte AR; Fichera LE
    Parasitology; 2019 Mar; 146(3):305-313. PubMed ID: 30301480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.
    Perin L; Moreira da Silva R; Fonseca KD; Cardoso JM; Mathias FA; Reis LE; Molina I; Correa-Oliveira R; Vieira PM; Carneiro CM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.